Hemostemix Inc. (CVE:HEM – Get Free Report) shares rose 38.1% during trading on Thursday . The company traded as high as C$0.15 and last traded at C$0.15. Approximately 605,625 shares traded hands during trading, an increase of 51% from the average daily volume of 401,760 shares. The stock had previously closed at C$0.11.
Hemostemix Stock Up 38.1 %
The firm has a market capitalization of C$12.63 million, a P/E ratio of -7.25 and a beta of 0.20. The business’s 50 day moving average is C$0.09 and its two-hundred day moving average is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Investing In Preferred Stock vs. Common Stock
- 3 Smart Picks: Discounted Stocks for Savvy Investors
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- NVIDIA Deal Ignites Aurora Stock’s Explosive Potential
- Golden Cross Stocks: Pattern, Examples and Charts
- Why AMD Stock Might Already Be This Year’s Best Buy
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
